CFO
LAB icon

Callan Family Office’s Standard BioTools LAB Stock Holding History

Callan Family Office’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,875
Closed -$14.3K – 908
2025
Q2 		$14.3K Buy
+11,875
New +$13.2K ﹤0.01% 922

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Callan Family Office's LAB Position: Q3 2025 in Review

Callan Family Office sold out of Standard BioTools (LAB) in Q3 2025, closing a stake of 11,875 shares — an estimated $14.3K sold.

Callan Family Office first reported a position in LAB in Q2 2025 and held it in 1 quarter. The position peaked at $14.3K in Q2 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q3 2025.

  • Callan Family Office reported no remaining Standard BioTools position as of Q3 2025 after selling out during the quarter.
  • Callan Family Office sold 11,875 Standard BioTools shares in Q3 2025, an estimated $14.3K.
  • Callan Family Office first reported a position in Standard BioTools in Q2 2025 and held it in 1 quarter.
  • Callan Family Office's Standard BioTools position peaked at $14.3K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2025.

Based on Callan Family Office's 13F filing for Q3 2025, filed 4 Nov 2025.